First US biosimilar gradually eroding Amgen's market share, Sandoz
Sandoz says gradual uptake of its biosimilar will eat away at Amgen’s filgastrim market share which stands at 76% four months after Zarxio’s entry in the US.
Archives for January 29, 2016
Albumedix buys Eleven's half-life boosting albumin assets
Novozymes’ albumin technologies division Albumedix has bought Eleven Biotherapeutics’ half-life extension assets.
All indications? Newer biosimilars may prompt US FDA extrapolation rethink says expert
While data extrapolation is acceptable in approving US biosimilars across the same indications as its reference, the practice will not be applicable for the next generation of copycat biologics, a biotech expert says.
Thawing market heats up: Biocision expands cell therapy tech offering
Biocision has revamped its cell thawing platform to accommodate larger vial sizes and started developing an automated system for cell therapies in cryopreservation bags.